ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

raludotatug deruxtecan

Also written as “R-DXd”, “Raludotatug Deruxtecan” and “DS-6000a”.

In Merck’s pipeline, Raludotatug deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-CDH6 IgG1 monoclonal antibody linked to a topoi. Its studies are mostly in Ovarian Neoplasms · Lung Neoplasms · Fallopian Tube Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 2 companies.

Drug pageRaludotatug deruxtecan: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 29, 202611 company-led studies, 11 open or runningCo-development: Daiichi Sankyo and Merck, Oct 2023Next primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only77 open or runningphase 3since Jul 29, 2026Jun 21, 2021Mar 27, 2029phase 2 · NCT06843447
Daiichi Sankyo44 open or runningphase 3since Nov 27, 2023Dec 16, 2020Dec 30, 2026phase 1 · NCT04707248
  • Named in Merck’s own pipeline as raludotatug deruxtecan (MK-5909), phase 3, as of Nov 2, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Daiichi Sankyo only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2020First study: phase 1 study in Carcinoma, Renal CellFirst studyNCT04707248 · 179 enrolled · United States, Japan
  2. Jul 21, 2022Named raludotatug deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 127
  3. Oct 19, 2023Merck develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Merck
  4. Nov 27, 2023Phase 3 study in Ovarian NeoplasmsNCT06161025 · 860 planned · United States, Australia, Brazil and more
  5. Oct 25, 2024Phase 2 study in Advanced Solid TumorNCT06660654 · 335 enrolled · United States, Belgium, China and more
  6. Aug 3, 2026Phase 3 study in Fallopian Tube NeoplasmsNCT07791732 · 600 planned

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in Carcinoma, Renal CellNCT04707248
  2. Feb 29, 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT06161025
  3. Jul 1, 2029Primary completion: phase 3 study in Fallopian Tube NeoplasmsNCT07791732
  4. Dec 30, 2029Primary completion: phase 2 study in Advanced Solid TumorNCT06660654

TargetBeta

“Raludotatug deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-CDH6 IgG1 monoclonal antibody linked to a topoi”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6) ”NCIt, by rule

Other programs on CDH6

ProgramCompanyFurthest phaseStudies
TJ102rulephrontline-biopharmaphase 21
Anti-CDH6 Antibody-drug Conjugate SIM0505rulenextcure-incphase 11

Studies

All 4 Daiichi Sankyo leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07791732Fallopian Tube Neoplasms3Not yet recruitingJul 1, 2029600
NCT06660654Advanced Solid Tumor · United States, Belgium, China and more2Active, not recruitingDec 30, 2029335
NCT06161025Ovarian Neoplasms · United States, Australia, Brazil and more3RecruitingFeb 29, 2028860
NCT04707248Carcinoma, Renal Cell · United States, Japan1Active, not recruitingDec 30, 2026179

How it is read

Names in the registry

  • “R-DXd”, 5 entries
  • “Raludotatug Deruxtecan”, 2 entries
  • “DS-6000a”, 2 entries
  • “R-DXD”, 1 entry
  • “Raludotatug deruxtecan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.